<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313534</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455645</org_study_id>
    <secondary_id>UCSF-035510</secondary_id>
    <secondary_id>UCSF-H45860-23712-02A</secondary_id>
    <nct_id>NCT00313534</nct_id>
  </id_info>
  <brief_title>Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer</brief_title>
  <official_title>A Phase I Study of NDGA in Patients With Non-Metastatic Biochemically Relapsed Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of&#xD;
      nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of nordihydroguaiaretic acid (NDGA) in patients&#xD;
           with nonmetastatic, biochemically relapsed prostate cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine prostate-specific antigen-modulating effects of NDGA in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral nordihydroguaiaretic acid (NDGA) twice daily on days 1-28. Treatment&#xD;
      repeats every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of NDGA until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Ran out of drug&#xD;
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity as measured by CTC v3.0</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) at baseline and on day 1 of each course</measure>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masoprocol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Androgen-dependent disease (testosterone ≥ 250 ng/mL)&#xD;
&#xD;
               -  Androgen-independent disease (testosterone &lt; 50 ng/mL)&#xD;
&#xD;
          -  Received prior definitive therapy for primary prostate cancer comprising any of the&#xD;
             following:&#xD;
&#xD;
               -  External-beam radiotherapy with or without hormonal therapy&#xD;
&#xD;
               -  Brachytherapy with or without pelvic external-beam radiotherapy or hormonal&#xD;
                  therapy&#xD;
&#xD;
               -  Radical prostatectomy with or without adjuvant or salvage radiotherapy&#xD;
&#xD;
               -  Cryotherapy&#xD;
&#xD;
          -  Must have evidence of disease progression, as evidenced by elevated prostate-specific&#xD;
             antigen (PSA) that has risen serially from post-definitive therapy nadir on 2&#xD;
             determinations taken ≥ 1 week apart&#xD;
&#xD;
               -  Elevated PSA, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  At least 1.0 ng/mL post radiotherapy or cryotherapy&#xD;
&#xD;
                    -  At least 4 ng/mL post radical prostatectomy&#xD;
&#xD;
               -  Must show disease progression after discontinuation of the antiandrogen (for&#xD;
                  patients with androgen-dependent disease receiving antiandrogen as part of&#xD;
                  primary androgen ablation)&#xD;
&#xD;
          -  No metastatic disease, confirmed by negative bone scan and negative CT scan or MRI of&#xD;
             abdomen/pelvis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST ≤ 1.5 times ULN&#xD;
&#xD;
          -  No other medical condition that would interfere with study therapy or compliance&#xD;
&#xD;
          -  No other active malignancy except previously treated squamous cell or basal cell skin&#xD;
             cancer or cancer that has been treated and considered to be at &lt; 30% risk of relapse&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 8 weeks since prior strontium-chloride Sr 89&#xD;
&#xD;
          -  More than 4 weeks since first dose of bisphosphonates&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery or radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal agents, including megestrol or steroids&#xD;
&#xD;
               -  Concurrent luteinizing hormone-releasing hormone analogs allowed to maintain&#xD;
                  castrate levels of testosterone&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent saw palmetto, finasteride, or any&#xD;
             herbal agent intended to lower PSA&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant androgen-deprivation therapy allowed for&#xD;
             androgen-dependent prostate cancer provided that all of the following are met:&#xD;
&#xD;
               -  No more than 8 months of androgen deprivation&#xD;
&#xD;
               -  At least 12 months since last day of effective androgen deprivation&#xD;
&#xD;
               -  Testosterone &gt; 250 ng/mL at enrollment&#xD;
&#xD;
          -  Prior hormonal therapy, chemotherapy, or investigational therapy for biochemical&#xD;
             relapse allowed&#xD;
&#xD;
          -  No concurrent chemotherapeutic, immunotherapeutic, or other investigational agents&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Ryan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>April 11, 2006</study_first_submitted>
  <study_first_submitted_qc>April 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Masoprocol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

